Brokerages expect Retrophin Inc (NASDAQ:RTRX) to announce earnings of $0.17 per share for the current fiscal quarter, according to Zacks. Zero analysts have made estimates for Retrophin’s earnings, with estimates ranging from $0.11 to $0.22. The business is expected to report its next quarterly earnings results on Wednesday, March 7th.
On average, analysts expect that Retrophin will report full year earnings of $0.39 per share for the current financial year, with EPS estimates ranging from $0.37 to $0.41. For the next fiscal year, analysts expect that the business will post earnings of $0.47 per share, with EPS estimates ranging from $0.26 to $0.68. Zacks’ earnings per share calculations are a mean average based on a survey of research firms that cover Retrophin.
Retrophin (NASDAQ:RTRX) last announced its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.21). Retrophin had a negative net margin of 33.79% and a negative return on equity of 10.13%. The company had revenue of $40.34 million for the quarter, compared to analysts’ expectations of $40.51 million. During the same period in the prior year, the company earned ($0.09) earnings per share. The company’s revenue for the quarter was up 18.8% on a year-over-year basis.
Shares of Retrophin (NASDAQ:RTRX) traded down $0.11 during midday trading on Friday, hitting $23.18. The stock had a trading volume of 142,528 shares, compared to its average volume of 294,014. Retrophin has a twelve month low of $15.55 and a twelve month high of $26.44. The stock has a market capitalization of $894.00, a P/E ratio of -17.56 and a beta of 1.45. The company has a debt-to-equity ratio of 0.15, a quick ratio of 3.83 and a current ratio of 3.88.
Large investors have recently bought and sold shares of the stock. SG Americas Securities LLC raised its position in Retrophin by 1.8% during the second quarter. SG Americas Securities LLC now owns 8,167 shares of the biopharmaceutical company’s stock valued at $158,000 after buying an additional 146 shares during the period. Legal & General Group Plc raised its position in Retrophin by 4.3% during the second quarter. Legal & General Group Plc now owns 8,664 shares of the biopharmaceutical company’s stock valued at $168,000 after buying an additional 355 shares during the period. Trexquant Investment LP acquired a new position in Retrophin during the third quarter valued at $203,000. Dynamic Technology Lab Private Ltd acquired a new position in Retrophin during the third quarter valued at $212,000. Finally, Campbell & CO Investment Adviser LLC acquired a new position in Retrophin during the third quarter valued at $249,000.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.